Postmenopausal oral estrogen therapy affects hemostatic factors, but does not account for reduction in the progression of subclinical atherosclerosis

Keyphrases

• Estrogen Therapy 100%
• Natural Estrogens 100%
• Hemostatic Factors 100%
• Subclinical Atherosclerosis 100%
• Carotid Artery Intima-media Thickness 71%
• Tissue Plasminogen Activator (t-PA) 57%
• Albumin 42%
• Estrogen 28%
• 17-estradiol 28%
• Estradiol 28%
• Fibrinogen 28%
• D-dimer 28%
• Plasminogen Activator inhibitor-1 (PAI-1) 28%
• Menopausal Hormone Therapy 28%
• Placebo 14%
• Thrombosis 14%
• Postmenopausal Women 14%
• Body Mass Index 14%
• Randomized Placebo-controlled Trial 14%
• Estrogen Effect 14%
• Atherosclerosis Progression 14%
• Negatively Associated 14%
• Index Revision 14%
• Reverse Causality 14%

Medicine and Dentistry

• Atherosclerosis 100%
• Estrogen Therapy 100%
• Hemostat 100%
• Oral 100%
• Intima-Media Thickness 62%
• Artery Intima 62%
• Carotid Artery 50%
• Diethylstilbestrol 50%
• Tissue Plasminogen Activator 50%
• Albumin 37%
• Placebo 25%
• Hormone Therapy 25%
• Fibrinogen 25%
• Plasminogen Activator Inhibitor-1 25%
• D-Dimer 25%
• Thrombosis 12%
• Postmenopause 12%
• Body Mass Index 12%
• Common Carotid Artery 12%
• F Factor 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Atherosclerosis 100%
• Hemostatic Agent 100%
• Diethylstilbestrol 50%
• Tissue Plasminogen Activator 50%
• Albumin 37%
• Placebo 25%
• Fibrinogen 25%
• D Dimer 25%
• Endocrine Therapy 25%
• Plasminogen Activator Inhibitor 1 25%
• Thrombosis 12%
• F Factor 12%